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ABSTRACT
ROBACH, P., Y. FULLA, K. R. WESTERTERP, and J.-P. RICHALET. Comparative Response of EPO and Soluble Transferrin
Receptor at High Altitude. Med. Sci. Sports Exerc., Vol. 36, No. 9, pp. 1493–1498, 2004. Purpose: Soluble transferrin receptor (sTfR)
classically raises with increased erythropoiesis, along with the rise in erythropoietin (EPO). However, the specific effect of
altitude-induced erythropoiesis on sTfR remains poorly documented. This study investigated the response of sTfR during high-altitude
exposure in human and verified that sTfR was related to EPO response in this case. Methods: EPO, sTfR, red cell volume (RCV),
ferritin, and iron intake were measured during: 1) experiment A (N  8, 31 d at 5000–8848 m), at sea level (SL), and at the simulated
altitude of 5000, 6000, 7000, and 8000 m; and 2) during experiment B (N  10, 7 d at 4350 m), at SL, after 3, 5, and 7 d at 4350 m
and 1–2 d after return to SL (RSL). Results: In experiment A, progressive decompression from SL to 8000 m induced a large parallel
rise in EPO (33.8-fold) and sTfR (5.9-fold), whereas ferritin was dramatically decreased and iron intake reduced. RCV was increased
after 31 d of decompression. In experiment B, EPO peaked at day 3 at 4350 m, then declined later at altitude and returned to baseline
values at RSL, whereas sTfR progressively rose at altitude (86%) and remained elevated during RSL (64%). Ferritin progressively
declined at 4350 m, whereas iron intake was unchanged. RCV was not enhanced after exposure to 4350 m. Conclusion: In summary,
sTfR mirrors EPO response for a given level of altitude hypoxia but differs from EPO response during transitory phases, such as early
acclimatization or reoxygenation. Analysis of sTfR may therefore account for altitude-related erythropoiesis, at a time when EPO is
blunted. Key Words: HYPOXIA, ACCLIMATIZATION, HEMATOCRIT, HEMOGLOBIN, ERYTHROPOIESIS
Exposure to high altitude enhances erythropoiesis,which promotes a rise in the number of circulatingred cells and hemoglobin mass. This process, one of
the main features of acclimatization, improves blood O2
carrying capacity in the hypoxic environment. Hypoxia-
induced erythropoiesis is triggered by the increased produc-
tion of erythropoietin (EPO), mainly originating from the
kidney (19). In humans, erythropoiesis is basically esti-
mated from serum EPO, which is accepted to be directly
related to the rate of renal EPO production.
For a given altitude, serum EPO increases within hours
after arrival and reaches a peak on days 1–2 at altitude, then
progressively declines to a level close to basal value
(1,8,31). Furthermore, the rise in serum EPO is oxygen
dependent, i.e., positively related to the degree of hypoxia
(10,16). During severe hypoxia, very high stimulation of
erythropoiesis may be illustrated by the dramatic increases
in serum EPO, previously observed in rats with 7.5% O2 (8)
and in humans at 6542 m (21).
On the other hand, the changes in erythropoietic activity are
associated with alterations in iron metabolism: high erythro-
poiesis, and subsequent red cell multiplication, implies high
iron needs by erythroid progenitors, in order to synthesize
heme, whereas the opposite occurs when erythropoiesis is low
(5). Therefore, erythropoiesis can be indirectly evaluated
through the analysis of iron uptake by the cell, namely by the
measurement of the transferrin receptor (TfR), a membrane
glycoprotein that regulates cellular uptake of iron from the
circulation. A soluble form of TfR (sTfR), identified in human
serum and closely related to tissue TfR (17), has made this
measure easy to perform and thus, routinely used. The link
between sTfR and erythropoiesis is evidenced by numerous
studies involving patients with erythropoietic disorders, in
which sTfR concentration was found closely related to the
alterations in serum EPO (2,14).
The question then arises, what is the response of sTfR
during high altitude exposure? Literature reveals that data
on sTfR during environmental hypoxia remain sparse and
mainly concern mild hypoxia (18,25,28). One might sup-
pose that, as for physiopathological situations associated
with high erythropoietic responses, sTfR likely reflects the
changes in EPO, i.e., increases with altitude-related eryth-
ropoiesis. This hypothesis is supported by the fact that the
expression of TfR in hypoxia is triggered by the same
transcription factor as EPO, namely hypoxia inducible fac-
tor (HIF-1) (20). Alternatively, the response of sTfR during
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exposure to high altitude could be different from those of
EPO, because sTfR is not only tightly coupled to erythro-
poiesis, but is also sensitive to mild iron deficiency (5,27),
and because a decrease in body iron stores occurs during
acclimatization to high altitude, as suggested by the decline
in serum ferritin (21).
The aim of the present study was 1) to characterize the
alterations in serum sTfR concentration in various altitude
conditions and 2) to test the hypothesis that serum sTfR
reflects EPO response during high altitude exposure. The
practical application of this study was to evaluate to what
extent the measure of sTfR, besides EPO and standard
hematology, could help to detect a recent high erythropoi-
etic activity, induced either by altitude sojourn or exogenous
erythropoiesis stimulation. Serum EPO and sTfR were eval-
uated in healthy volunteers: A) during a progressive (31 d)
decompression in a hypobaric chamber up to the simulated
altitude of 8848 m; B) during and after a 1-wk stay at the
altitude of 4350 m in a field laboratory. Experiment A
investigates the effect of successive levels of high altitude,
increasing by a step-by-step manner (near steady state con-
ditions), whereas experiment B focuses on the acute on- and
off-responses during a shorter stay at a given altitude.
METHODS
Subjects and Procedures
Experiment A. This experiment was part of Operation
Everest III, a simulated ascent of Mt. Everest in a hypobaric
chamber at COMEX S.A. in Marseille, France. Complete
details of this study have been published previously (22,23).
The subjects were eight male volunteers, not acclimatized to
high altitude before the experiment. Their mean ( SD) age,
height, body mass, and sea level V̇O2max were 27  4 yr,
180  6 cm, 74  7 kg, and 57  5 mL·min1·kg1,
respectively. Temperature and hygrometry in the chamber at
the time of measurements were controlled between 18 and
24°C, and 30 and 60%, respectively. The study was ap-
proved by the Ethics Committee of the University Hospital
of Marseille, France. Subjects were fully informed of all
testing procedures and the associated potential risks in-
volved before providing their written consent.
The ascent profile is presented in Figure 1, as described
elsewhere (22,23). Subjects were evaluated at sea level and
during a 31-d period of decompression, starting from 5000
to 8848 m (barometric pressure, PB  253 mm Hg). The
decompression was preceded by a 6-d preacclimatization in
the French Alps, with 1 d at 3650 m and 6 d at 4350 m
(Vallot Observatory), without performing any scientific
measurement. For the present study, the measurements were
performed at sea level (SL), at the simulated altitude of
5000 m (PB  422 mm Hg), at 6000 m (PB  370 mm Hg),
at 7000 m (PB  324 mm Hg), and at 8000 m (PB  284 mm
Hg). For each altitude stage, sampling was made in the
morning on day 2 (Fig. 1).
Experiment B. This study was performed before, dur-
ing, and after a 1-wk stay at the Vallot Observatory on
Mont-Blanc (altitude  4350 m; PB  448 mm Hg). Com-
plete details of this study are given elsewhere (24). The
subjects were 10 male volunteers, not acclimatized to high
altitude before the study. Their transportation to- and from-
the high altitude laboratory was done by helicopter. They
had a mean ( SD) age of 29  7 yr, height of 175  4 cm,
body weight of 69  8 kg, and V̇O2max of 46  3
mL·min1·kg1. Temperature inside the observatory was
controlled between 18 and 23°C. This study was approved
by the Ethics Committee of the Necker Hospital, Paris,
France. Subjects were fully informed of all testing proce-
dures and the associated potential risks involved before
providing their written consent.
The subjects were evaluated at sea level (SL), during the
7-d stay at 4350 m on the third (H3), fifth (H5), and seventh
(H7) days, then 12 h (RSL1) and 24 h (RSL2) after return
to sea level. During the high altitude sojourn, the level of
physical activity remained low. The investigations at sea
level, high altitude and RSL2 were performed simulta-
neously in the morning. For RSL1, all the subjects were
evaluated simultaneously on evening at 12 h postaltitude.
Blood Analyses
Experiments A and B. All the blood samples were
collected by venipuncture from a forearm vein, at rest in a
sitting position, after an overnight fast. Blood samples were
centrifuged and separated serum stored at 80°C for further
analysis. Serum concentration of sTfR was measured by
chemoluminescence, using a mouse monoclonal antibody,
coupled to biotin and labeled by acridinium ester (Nichols
Advantage). The intra- and interassay coefficients of vari-
ation for sTfR measurement, determined in our laboratory,
were 5.6% and 8.3%, respectively. Serum concentration of
EPO was measured by chemoluminescence, using a mouse
monoclonal antibody labeled with acridinium ester and a
sheep polyclonal antibody labeled with biotin (Nichols Ad-
vantage). The intra- and interassay coefficients of variation
for EPO measurement, determined in our laboratory, were
5.2% and 7.1%, respectively. Serum ferritin concentration
was measured using an immunoradiometric assay (RIA-
gnost Ferritin, Behring, Marburg, Germany). The intra- and
interassay coefficients of variation for ferritin measurement,
FIGURE 1—Simulated ascent profile of experiment A (Operation
Everest III). Arrows indicate days of blood sampling.
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determined in our laboratory, were 1.9% and 5.7%, respec-
tively. Hemoglobin concentration ([Hb]) was measured by
spectrophotometry (CO-oximeter, model 270, Bayer Diag-
nostics) and the hematocrit by microcentrifugation.
Iron Intake
Experiments A and B. Iron intake from food and bev-
erages was measured daily in a dietary record during the
whole experiment. The subjects recorded intake during each
meal and snack, using table scales to weigh individual food
items and a graduate container for volume of drinks. Food
tables (7) were used to determine daily iron intake. Sea level
values were averaged from data obtained during four (ex-
periment A) and three (experiment B) consecutive days;
altitude values in experiment A were averaged from data
obtained during the first 2 d at each altitude stage.
Red Cell Volume Measurement
The respective methods and results on intravascular fluid
compartments have been previously described in details for
experiment A (23) and for experiment B (24). In experiment
A, red cell volume was determined by Evans blue dilution
(T-1824): the data mentioned in the present report are those
obtained at sea level, before, and 1–3 d after the end of
hypobaric exposure. In experiment B, red cell volume was
measured by a carbon monoxide rebreathing technique: the
data mentioned in the present report are those obtained at
sea level, before, and 2 d after the end of the altitude
sojourn.
Statistics
Experiments A and B. Data are presented as arith-
metic mean  SD. Because EPO, sTfR, and ferritin values
are not normally distributed, median and 25th and 75th
percentiles are also shown for these parameters. A one-way
ANOVA with repeated measures was used to compare the
effect of altitude and return to sea level. A Student New-
man-Keuls test was used for multiple comparisons. A Pear-
son product-moment correlation test was used to analyze the
relationship between two quantitative variables. Differences
were considered significant at P  0.05.
RESULTS
Experiment A. [Hb] and hematocrit progressively in-
creased as simulated altitude was raised (Table 1). Serum
EPO progressively increased as decompression was raised
(Fig. 2A). A 33.8-fold increase in mean EPO occurred from
sea level (18.8  4.6 U·L1) to 8000 m (653.8  513.7
U·L1). Serum sTfR followed a similar time course, being
increased from 17.5  4.2 nmol·L1 before decompression
to 121.4  54.8 nmol·L1 at the simulated altitude of
8000 m (Fig. 2A). Serum ferritin, sharply decreased with
hypobaric exposure, reaching very low values at 8000 m
FIGURE 2—Variations in serum erythropoietin (EPO), soluble trans-
ferrin receptor (sTfR), and ferritin (A) at sea level (SL) and during a
31-d progressive decompression (experiment A: N  8, except for
8000 m, where N  7); and (B) at SL and during and after a 7-d
sojourn at 4350 m (experiment B: N  10, H3, H5, and H7 are third,
fifth, and seventh days after arrival at 4350 m, respectively; RSL1 and
RSL2 are 12 h and 24 h after return to sea level, respectively). Values
are median and 25th and 75th percentiles. The ordinate ranges for
EPO, sTfR, and ferritin are different between A and B. * P < 0.05
altitude or return to sea level vs sea level.
TABLE 1. Venous hemoglobin concentration ([Hb]) and venous hematocrit (Hct) 1) at sea level (SL) and during progressive simulated exposure to 8848 m (experiment A); and
2) before (SL), during a 1-wk exposure to 4350 m and after return to sea level (RSL1: 12 h; RSL2: 24 h) (experiment B).
Experiment A
SL 5000 m 6000 m 7000 m 8000 m
[Hb] (gdL1) 14.8  1.4 16.4  1.2* 16.8  1.0* 16.7  1.3* 18.4  1.5*
Hct (%) 46.3  3.0 52.0  3.3* 53.3  2.9* 55.6  2.9* 56.6  5.0*
Experiment B
SL 4350 m RSL1 RSL2
[Hb] (gdL1) 14.9  0.8 16.8  1.2* 16.3  1.0* 15.4  1.0*
Hct (%) 44.0  2.6 48.5  3.1* 47.7  3.2* 44.7  3.1
Values are means  SD: Experiment A: N  8, except for 8000 m (N  7). Experiment B: N  10, blood samples for [Hb] and Hct were obtained on day 7 at 4350 m. For both
experiments: * P  0.05 vs sea level.
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(6.5  4.1 g·L1) (Fig. 2A). The subjects experienced an
initial decrease in total iron intake as decompression started
(Fig. 3A). Iron intake then remained stable with altitude gain
but decreased further at 8000 m. Red cell volume was
significantly increased by the hypobaric exposure, from
2.52  0.43 L at sea level before decompression, to 3.24 
0.80 L (P  0.05) 1–3 d after return to sea level (23).
Finally, individual sTfR data were correlated to the corre-
sponding EPO data (N  39): [sTfR]  33.298  0.116 
[EPO]; R2  0.83; P  0.0001.
Experiment B. [Hb] and hematocrit rose significantly
at high altitude but had almost returned to initial values on
day 2 after return to sea level (Table 1). Serum EPO sig-
nificantly increased during high-altitude exposure (Fig. 2B).
EPO reached a peak on day 3 at 4350 m, then declined to
lower values, still above prealtitude levels. EPO had re-
turned to basal values 12 h after descent from 4350 m. In
contrast, serum sTfR progressively increased at high alti-
tude, reaching a peak after 7 d at 4350 m (Fig. 2B). During
the first 2 d of return to sea level, sTfR remained elevated
above basal values. Serum ferritin progressively decreased
at high altitude, and this decrement was not reversed during
early return to sea level (Fig. 2B). Iron intake was not
altered by 1 wk spent at 4350 m (Fig. 3B). Finally, this 1-wk
stay at 4350 m did not induce any increase in red cell
volume, mean values being 2.34  0.11 L at sea level before
altitude exposure, and 2.29  0.26 L on day 2 after return
to sea level (24). Finally, individual sTfR data were not
correlated to the corresponding EPO data (N  60): [sTfR]
 26.102  0.032  [EPO]; R2  0.01; P  0.39.
DISCUSSION
The main finding of the present study was that sTfR
globally reflected EPO response for a given level of envi-
ronmental hypoxia but was disconnected from EPO changes
during transitory phases, such as early acclimatization and
return to sea level. Thus, although our results confirm in
hypobaric hypoxia what has been previously shown from
various erythropoietic disorders, that is, that the rise in sTfR
was strongly dependent on enhanced erythropoiesis, they
also suggest that the control of sTfR production may differ
from those of EPO during hypoxia-induced erythropoiesis.
EPO response. Our data on serum EPO time course at
4350 m are in agreement with numerous previous works
(1,8,13,31) showing that, for a given altitude, serum EPO
increased during the first days, then progressively declined,
in spite of the persistence of the renal hypoxic stimulus. The
reason why serum EPO follows a biphasic response at
altitude still remains unclear. It was previously suggested
that such changes may reflect the transient imbalance be-
tween 1) an early and permanently high renal EPO produc-
tion and 2) a delayed rise in EPO consumption (12). Indeed,
studies from anemic patients with low or high erythroid
activity strongly suggest that serum EPO is regulated both
by the rate of renal production and by the rate of utilization
by erythroid cells (6). On the other hand, data from molec-
ular biology may also account for EPO pattern at high
altitude, because the expression of HIF-1 itself, which is known
to play a key role on EPO gene activation (15), rapidly in-
creases, then progressively declines in hypoxia (29).
To our knowledge, the measurement of serum EPO in
experiment A is the only one obtained in human up to the
simulated altitude of 8000 m, corresponding to a mean
arterial PO2 of 37 mm Hg and a mean arterial O2 saturation
of 68% (22). However, the magnitude of EPO increase at
8000 m (34-fold) was not higher than the 37-fold increase in
serum EPO previously collected in field conditions at
6542 m (21) and much lower that the rise in serum EPO
observed in rats acutely exposed to 7.5% O2 (8000 m) (8).
Thus, EPO values measured at 8000 m in experiment A,
although very high, probably did not reflect the potential
maximal increase in serum EPO with this level of hypoxia,
because the subjects reached 8000 m after having been
exposed to progressive hypobaria for 4 wk.
sTfR response. Previous reports on sTfR response dur-
ing ambient hypoxia are few and mainly concern intermit-
tent exposure to mild hypoxia (2500–3500 m) in athletes: in
these works, sTfR was found slightly increased after 1–3 wk
of intermittent hypoxia (18,25,28). Conversely, sTfR was
not found higher during a 10-d sojourn at 3600 m in un-
trained subjects (13). Finally, two investigations demon-
strated that people living at 1600 m (3) or 3000–4300 m (4)
experienced a significant increase in sTfR. In the present
study, first, the sixfold increase in sTfR observed at 8000 m
suggests that a very high TfR expression can be elicited in
healthy human during severe hypoxia. The magnitude of
this increase may be compared with the 9.6-fold rise in sTfR
found in -thalassemia patients, who experience the highest
range of sTfR levels (5). Second, serial measurements of
sTfR at 4350 m demonstrate a specific time course, different
from EPO response; particularly, sTfR remains elevated at
a time when EPO is blunted (1 wk of acclimatization) or
suppressed (return to sea level).
From the present data, the question arises, what are the
controlling factors of sTfR response during high altitude
FIGURE 3—Variations in daily iron intake A) at sea level (SL) and
during a 31-d progressive decompression (experiment A: N  8, except
for 8000 m, where N  7); and B) at SL and during and after a 7-d
sojourn at 4350 m (experiment B: N  10, H1 to H7 are first to seventh
days after arrival at 4350 m, respectively; RSL1 and RSL2 are 12 h
and 24 h after return to sea level, respectively). Values are mean  SD;
* P < 0.05 altitude vs sea level; ** P < 0.05 8000 m vs other altitude
stages.
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exposure? The first determinant of sTfR production is the
rate of erythropoiesis, as supported by studies from patho-
physiology (2,14). This is confirmed in healthy subjects
in experiment A by the close relationship found between
sTfR and EPO during gradual decompression. Two factors
may account for this relationship: 1) HIF-1, which up-
regulates both EPO (15) and sTfR (20) expressions during
hypoxia; and 2) EPO, which can directly act on TfR ex-
pression (26).
The second determinant of sTfR production is iron avail-
ability: iron deficiency raises sTfR, whereas the opposite
occurs when iron stores are high (5). In the present study, we
estimated the level of iron stores through serum ferritin.
During prolonged high altitude exposure, serum ferritin
classically decreases (21), because of the high iron needs for
hemoglobin synthesis. Furthermore, ferritin expression may
be down-regulated by hypoxia (30). Nevertheless, the
present data showed that prolonged exposure to severe hyp-
oxia induced a dramatic drop (92%) in ferritin level (mean
of 6.5 g·L1 at 8000 m), which was under the cut-off of 15
g·L1, indicating absent iron stores in humans (11). Un-
doubtedly, besides high erythropoiesis, the depleted iron
stores in our subjects contributed to the large rise in sTfR
during gradual decompression. Such a depletion in iron
stores (low ferritin and high sTfR) has to be related to the
likely dramatic change in iron distribution from circulating
iron to hemoglobin, because the 720-mL increase in red cell
mass experienced by our subjects at simulated altitude,
caused mobilization of about 700 mg of storage iron. Fi-
nally, we cannot exclude that the decrease in iron intake (see
Fig. 3A), related to an overall decrease in food intake due to
altitude-induced anorexia, may have contributed to lower
ferritin (32).
In the present study, we also showed that sTfR was not
related to EPO response during transitory phases, i.e., early
acclimatization and return to sea level. Our result may be
compared to a previous report, indicating that athletes who
received recombinant human EPO experienced an early and
total blunting of EPO after treatment, whereas sTfR re-
mained elevated for as long as 2 wk after treatment (4). The
dissociation we observed in the present study could be
explained, at least in part, by the different half-life of both
substances. EPO half-life in the circulation is very short (2
h) (9), whereas sTfR half-life seems to be long (estimated
from some animal studies), even if, to our knowledge, it has
not been measured yet (Beguin, personal communication).
In this scheme, the progressive increase in sTfR over 1 wk
at 4350 m would reflect the persistence of a high erythro-
poietic activity over time at high altitude, which may not be
demonstrated from EPO data. Furthermore, high sTfR dur-
ing early return to sea level may account for a still supranor-
mal erythropoietic activity, at a time when EPO increase
was totally suppressed. Thus, even if both sTfR and EPO
assess erythropoiesis, the rate of production and/or degra-
dation of each molecule would be controlled differently.
Finally, with respect to iron availability, the response of
sTfR during and after exposure to 4350 m was unlikely
related to iron deficiency, as suggested by the modest dec-
rement in ferritin throughout the study (lowest mean value
 45.2 g·L1).
In summary, we showed that sTfR globally reflected EPO
response for increasing levels of hypoxia but was discon-
nected from EPO changes during transitory phases, such as
early acclimatization and return to sea level. The present
results suggest that sTfR may be used as an index of alti-
tude-related erythropoiesis, when EPO response is blunted.
In practice, the detection of a recent high erythropoietic
activity (altitude sojourn or exogenous erythropoiesis stim-
ulation) may be achieved through the measurement of sTfR,
at a time when EPO, hematocrit, hemoglobin, or red cell
volume is not different from baseline.
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